Lupin Ltd Q1 FY27 Earnings Call: Trims EBITDA Margin Guidance to 24-25%, Posts Record Revenue of Rs. 8,277 Cr

Lupin Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter Sets High Base

• Record revenue of Rs.8,277 crores — up 32% YoY, marking the 16th consecutive quarter of YoY growth.
• EBITDA of Rs.2,464 crores — up 50% YoY, with margin expanding to 30% (vs 26.6% in Q1 FY25-26).
• Gross margin improved to 74.6% — up 330 bps YoY, driven by favourable product mix, higher India profitability, and cost efficiencies.
• US business recorded $366 million — up 43% YoY (30% CC), driven by higher base volumes but partially offset by Mirabegron competition.
• India prescription business grew 15.1% YoY — at 1.1x IPM (13.5%), with chronic mix improving to ~67% (from ~65% in FY25-26).
• R&D spend at 7.4% of sales — FY27 full-year R&D guided at ~8% of sales; pipeline includes 50+ active products.
• Operating working capital at Rs.8,260 crores (90 days) — net cash of Rs.2,831 crores (down from Rs.4,636 crores due to Bishu Pharma acquisition); ROCE at 29.5%.

Near-Term Pressure, FY28 Inflection Point

• US revenue guided at $1.1-1.2 billion for FY27 — Q1 actual of $366 million implies a quarterly run-rate of $250-280 million for the rest of the year.
• Sharp step-down driven by Tolvaptan competition — Apotex and Teva entering in Q2 FY27, with a potential fourth entrant in September 2026, creating a four-player market; Myhibbin already faced pressure in Q1 with full-quarter impact from Q2 onward.
• Return to growth trajectory from FY28 — on a base of ~$1.1-1.2 billion in FY27, led by FTFs, biosimilars, 505(b)(2) products, and 60+ injectables and respiratory products.
• Key FY27 launches include Pegfilgrastim (H2) — along with Dalbavancin injectable (505B2), fluticasone nasal spray, Sugammadex, epinephrine, Raltegravir (exclusive FTF), and terbutaline injection.
• Key FY28 launches include Apixaban 505(b)(2) — plus diazepam nasal spray, epinephrine nasal spray, Ivacaftor (exclusive FTF), and midazolam nasal spray.
• Apixaban 505(b)(2) targeting FDA approval by September 2026 — commercial quantities by January 2027, launch in summer 2027 with 10-12 months exclusivity before generic entrants expected early FY28-29.
• Respiratory portfolio contributes over 20% of base business — Albuterol US market share stabilized at 16%; Dulera filed, Respimat filing this fiscal year (FY27), and albuterol ANDA to be filed in FY27.

India Outperformance, Respiratory & Biosimilar Build

• India formulation business grew 13.9% YoY — core prescription up 15.1% (1.1x IPM), diabetes segment grew 31.8% YoY with semaglutide injection launch and vial/oral dosage forms expected in H2 FY27.
• Management targets India business to outperform IPM by 1.2-1.3x — aiming to increase chronic segment share to 70% in five years and achieve "1/3 of India revenues from novel proprietary products in 10 years" (Segment 2).
• Other developed markets grew 48% YoY — now 14% of total sales (vs 11% in FY25-26), with Europe up 83% YoY; consolidation of Suven Pharma began this quarter.
• Emerging markets revenue grew 52% YoY — led by Brazil (117% in local currency, driven by Depo-Medrol), South Africa, and Philippines.
• Innovation strategy targets 60-70 innovative product launches over 10 years — management aims for 1/3 of India revenue from innovative products; over the next three years, 80 launches in India planned, with 3-4 truly innovative.
• Respiratory platform: FY27 is a significant filing year for MDI products — Ellipta platform showed positive PK on first product; Respimat Spiriva device challenge cleared, filing expected in FY27; Fluticasone nasal spray RX approval expected in FY27, OTC approval in FY28.
• Biosimilars expected to ramp to "a couple of hundred million dollars" over the next three years (Segment 7) — across US and Europe, driven by pegfilgrastim (US), ranibizumab (Europe via Visupharm), and aflibercept (launch in FY28-29).

EBITDA Guidance Trimmed Amid Tolvaptan & Cost Pressures

• EBITDA margin guidance for FY27 trimmed to 24-25% — down from Q1's 30% print, reflecting lower Tolvaptan realization, increased competition, and input cost inflation from geopolitical tensions.
• Staff cost and other expenses rising due to increments, hiring, and FX impact — management cited potential EBITDA margin volatility below 20% in some quarters of FY27.
• Adjacencies (diagnostics, digital, OTC, CDMO) currently loss-making — impacting EBITDA margins by 1-1.5% in FY27; management expects diagnostics to break even in FY28.
• Tolvaptan market share increased QoQ in Q1 — management expects to defend share but will concede some to new entrants due to specialty pharmacy dynamics and REMS program.
• Myhibbin already faced pressure in Q1 — full-quarter impact from Q2 onward; US competitive intensity and geopolitical headwinds expected to moderate H2 performance.
• Gross margin improved 330 bps YoY to 74.6% — Q1 not impacted by input cost inflation due to inventory carryforward, but subsequent quarters will be affected.
• Effective tax rate at 29.8% in Q1 — guided at 27-28% for full year FY27.

Double-Digit Growth in Key Markets, Complex Generics Scale-Up

• High single-digit revenue growth guidance reiterated for FY27 — with EBITDA margins around 25%, but H2 moderation expected due to US competitive intensity and geopolitical headwinds.
• US revenue of $1.1-1.2 billion for FY27 — with return to growth trajectory from FY28 led by FTFs, biosimilars, and 505(b)(2) products.
• Double-digit growth (10-20%) guided for other developed markets — over FY27 and FY28, with Europe growth at 10-20% level post-Q2 FY27, driven by Visupharm acquisition pipeline.
• Pipeline of 50 FTFs and 21 exclusives — management targets "doubling the complex generics business over the next three to five years" from FY27 (Segment 14).
• Germany's doubled rebate policy impacts part of the portfolio — management cited that biosimilars like Ranibizumab and Flaberset are now outside AOK tenders, creating a branded opportunity.
• France is "doubling down on biosimilars" (Segment 8) — with incentives for substitution as "over $100 billion worth of biologics lose patent protection in the next 5-10 years" (Segment 8, partner forecast).
• ESG: 41% reduction in greenhouse gas emissions and 45% water recycling achieved — Lupin included in Time World's Most Sustainable Companies 2026 list for the first time.